Does corporate social responsibility of pharmaceutical manufacturing enterprises decrease debt financing costs? Economic implications through a moderated mediation model
Bibliographic Data
| ID | 22430784 |
|---|---|
| Authors | Yuegang Chen (0009-0004-6189-5562, Shanghai University), Feiyu Mao (0009-0007-4927-1265, Shanghai University), Zhixuan Liu (0000-0002-5968-0085, Shanghai University), Yan Wu (0000-0002-0290-4084, Shanghai Lixin University of Accounting and Finance) |
| Year | 2026 |
| Volume | 32 |
| Issue | 3 |
| Pages | 963-995 |
| Publication date | 2026-03-16 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Technological and Economic Development of Economy (JOURNAL) |
| Journal identifiers | ISSN: 2029-4913 • E-ISSN: 2029-4921 |
| Publisher | Vilnius Gediminas Technical University (PUBLISHER • LT) |
| DOI | 10.3846/tede.2026.25480 |
| OpenAlex | W7136426136 |
| Language | EN |
| References cited | 84 |
In today’s complex economy, debt financing costs play a crucial role in shaping corporate competitiveness and are significantly shaped by stakeholder interests. This study focuses on the pharmaceutical manufacturing industry, exploring how Corporate Social Responsibility (CSR) affects the debt financing costs, with CSR further divided into strategic CSR and altruistic CSR. Drawing on the data of 286 pharmaceutical enterprises publicly traded on China’s A-share market during the 2010–2021 period, we construct a moderated-mediation framework to examine the complex mechanisms by which CSR affects debt financing costs. The findings show that stronger CSR efforts are linked to decreased debt financing costs. Financial performance acts as a mediator in this relationship, while media attention serves as a moderator. Specifically, strategic CSR initiatives, enterprises that are privately-owned, companies positioned in the eastern areas of China, and strong medical regulation witness a more significant reduction in financing costs. Furthermore, we find that compared to other industries, the fulfilment of social responsibility by pharmaceutical manufacturing enterprises plays a more crucial role in the sustainable development of the enterprise. This study examines the mechanisms through which pharmaceutical manufacturing firms reduce debt financing costs by fulfilling Corporate Social Responsibility (CSR), contributing to understanding of CSR’s economic value creation China’s emerging economy context. By incorporating firm-level and regional economic variations, the research addresses a gap in the existing literature and provides insights for pharmaceutical companies to optimize their financing strategies and attain sustainable economic development in emerging economies. First published online 16 March 2026
Corporate social responsibility · Debt · Emerging markets · Mediation · Moderated mediation · Social responsibility · Stakeholder · Stakeholder engagement · Business and Economic Development · Corporate Social Responsibility Reporting · Energy, Environment, Economic Growth
Stakeholder Theory
Does product market competition foster corporate social responsibility? Evidence from trade liberalization
Corporate Social Responsibility and Investment Efficiency
Heterogeneous green innovations and carbon emission performance
The Business Case for Corporate Social Responsibility
Mapping the Sustainable Development Goals Relationships
Defining CSR
Maximizing Business Returns to Corporate Social Responsibility (CSR)
Testing Trade-Off and Pecking Order Predictions About Dividends and Debt
Mediation in experimental and nonexperimental studies
Punishment by Securities Regulators, Corporate Social Responsibility and the Cost of Debt
Board Diversity and Corporate Social Responsibility
Corporate Social Responsibility (CSR) Implementation
Pharmaceutical Industry in the Global South
Envisioning smart and sustainable healthcare
The moderator–mediator variable distinction in social psychological research
| Highly cited | No |
|---|